Asian Growth Companies Insiders Are Betting On

In the midst of global economic uncertainty and inflation concerns, Asian markets have shown resilience, with some regions experiencing modest growth despite external pressures like new trade tariffs. In this environment, companies with high insider ownership often signal confidence from those who know the business best, making them potential candidates for investors seeking growth opportunities.

Top 10 Growth Companies With High Insider Ownership In Asia

Click here to see the full list of 667 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.

Let's review some notable picks from our screened stocks.

Jiangyin Jianghua Microelectronics Materials (SHSE:603078)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Jiangyin Jianghua Microelectronics Materials Co., Ltd is a Chinese company that manufactures and supplies wet electronic chemicals for microelectronics and optoelectronics, with a market cap of CN¥7.35 billion.

Operations: The company generates revenue by producing and providing wet electronic chemicals for the microelectronics and optoelectronics sectors in China.

Insider Ownership: 20.9%

Jiangyin Jianghua Microelectronics Materials is experiencing robust growth, with revenue forecasted to increase by 18.3% annually, surpassing the broader Chinese market's growth rate. Despite a slight decline in net income to CNY 98.63 million for 2024, earnings are projected to grow significantly at 25.4% per year over the next three years. Insider ownership remains strong with no substantial insider trading activity recently reported, supporting confidence in its growth trajectory.

• Click here and access our complete growth analysis report to understand the dynamics of Jiangyin Jianghua Microelectronics Materials.
• In light of our recent valuation report, it seems possible that Jiangyin Jianghua Microelectronics Materials is trading beyond its estimated value.

Gan & Lee Pharmaceuticals (SHSE:603087)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Gan & Lee Pharmaceuticals is a biopharmaceutical company focused on the research, development, production, and sale of insulin analog APIs and injections in China with a market cap of CN¥27.41 billion.

Operations: The company generates revenue of CN¥2.95 billion from its activities in developing, producing, and selling insulin and related products.

Insider Ownership: 36.6%

Gan & Lee Pharmaceuticals is poised for strong growth, with revenue expected to rise by 27.7% annually, outpacing the broader Chinese market. Earnings are projected to grow significantly at 43.8% per year over the next three years. The company has initiated a Phase 2 clinical trial for bofanglutide in the US, highlighting its innovative efforts in GLP-1 therapy for weight management. Despite low forecasted return on equity and unsustainable dividends, insider ownership remains substantial without recent significant trading activity.

• Click to explore a detailed breakdown of our findings in Gan & Lee Pharmaceuticals' earnings growth report.
• Insights from our recent valuation report point to the potential overvaluation of Gan & Lee Pharmaceuticals shares in the market.

Naruida Technology (SHSE:688522)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Naruida Technology Co., Ltd. manufactures and sells polarized multifunctional active phased array radars in China, with a market cap of CN¥15.14 billion.

Operations: The company's revenue is derived entirely from its Scientific & Technical Instruments segment, which amounts to CN¥345.28 million.

Insider Ownership: 17.8%

Naruida Technology demonstrates robust growth potential with forecasted revenue expansion of 50.3% annually, significantly outpacing the broader Chinese market. Earnings are expected to grow at a substantial rate of 68.4% per year over the next three years, despite a low projected return on equity of 18.4%. Recent earnings showed sales rising to CNY 345.28 million for 2024, and insider ownership remains strong with no significant trading activity reported recently.

• Delve into the full analysis future growth report here for a deeper understanding of Naruida Technology.
• The valuation report we've compiled suggests that Naruida Technology's current price could be inflated.

Next Steps

• Get an in-depth perspective on all 667 Fast Growing Asian Companies With High Insider Ownership by using our screener here.
• Want To Explore Some Alternatives? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com